NetScientific PLC Glycotest strengthens IP portfolio
12 Setembro 2016 - 3:01AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
12 September 2016
("NetScientific" or the "Company" or the "Group")
Glycotest Strengthens Intellectual Property Portfolio with
Japanese Patent Grant
Japanese patent joins five other patents to add significant
protection to core technology
London, UK - 12 September 2016 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, announces that one of its portfolio
companies, Glycotest, has been granted a Japanese patent for its
core technology for early detection of life threatening liver
disease.
Glycotest now holds a total of six patents in Australia, the US
and Japan, covering the use of over 50 unique glycoprotein
biomarkers for the diagnosis of liver cancers and other liver
diseases.
Commenting on the news, François R. Martelet, Chief Executive
Officer of NetScientific and Chairman of Glycotest said: "We are
delighted that the Japanese patent can now be added to Glycotest's
rising number of patents which add to the breadth of the IP for its
liver disease diagnostic platform. These granted patents and
additional pending applications put Glycotest in a strong position
to further protect its proprietary technology as it continues to
grow."
The full text of the announcement issued by Glycotest on 12
September 2016 is as follows:
Glycotest Intellectual Property Portfolio Strengthened by Grant
of Japanese Patent
New York, NY-September 12, 2016-Glycotest Inc., announced today
that a Japanese patent has been granted that provides important
protection of the Company's core technology for early detection of
life threatening liver disease.
Glycotest is a private liver disease diagnostics company
commercializing new and unique blood tests for liver cancers and
fibrosis-cirrhosis. The Company's mission is to reduce mortality
and increase survival for the growing population at risk from
serious liver diseases. Glycotest employs unique non-invasive blood
tests based on proprietary serum biomarkers, biomarker panels and
assay technology that exploit novel sugar-based disease signal
chemistry.
The Japanese patent announced today joins five other patents
previously granted in the United States and Australia which have
been licensed exclusively and on a worldwide basis to Glycotest by
Drexel University College of Medicine and the Blumberg Institute of
the Hepatitis B Foundation, both in the Philadelphia area. These
patents cover the use of over 50 unique glycoprotein biomarkers for
the diagnosis of liver cancers and other liver diseases. In
addition, the Company soon expects to announce positive
developments in the patent protection of the proprietary assay
technology required to measure these novel biomarkers. Together
these granted patents and the additional pending applications
protect Glycotest's proprietary liver disease diagnostic
platform.
Commenting on these developments, Glycotest's Chief Executive
Officer Lawrence Cohen said, "The Glycotest patent portfolio is
becoming substantial and we expect more good news in the coming
year regarding our intellectual property position. Our IP portfolio
along with the outstanding clinical results of our HCC Panel
achieved to date are forming the base of what we expect to be a
very strong company in liver disease diagnostics."
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710
(NOMAD and broker) Jonathan 7600
Senior / David Arch / Ben
Maddison
Consilium Strategic Communications Tel: +44 (0)20 3709
Mary-Jane Elliott / Chris 5700
Gardner / Jessica Hodgson netscientific@consilium-comms.com
/ Chris Welsh / Laura Thornton
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company
commercializing novel clinical laboratory testing services for
patients at risk for liver cancers and fibrosis-cirrhosis. The
Company was founded in 2012 on proprietary technology that
originated at the Philadelphia area institutions Baruch S. Blumberg
Institute and Drexel University College of Medicine. Learn more at
www.glycotest.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUAVARNBAKAUR
(END) Dow Jones Newswires
September 12, 2016 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024